Bone Marrow-Derived Mesenchymal Stromal Cells found Safe and Effective for Knee Osteoarthritis

Primary tabs

NEWS
Bone Marrow-Derived Mesenchymal Stromal Cells found Safe and Effective for Knee Osteoarthritis

A study issued in the 'Journal of Translational Medicine' showed that single intraarticular injection of in vitro expanded autologous Bone Mesenchymal stromal cells (BM-MSCs) is a safe and feasible method that results in long-term clinical and functional improvement of knee osteoarthritis (OA).

For knee OA treatment, the mesenchymal stromal cells (MSCs) have been found to be promising. Many short-term clinical trials have demonstrated the safety and usefulness of MSCs. However, there is a lack of confirmed evidence on the long-term effects of MSC in OA patients. The authors have investigated the patients included in their previous randomized clinical trial to determine the long-term clinical effect.

This phase I/II multicenter randomized clinical trial with active control was performed between 2012-2014. A total of 30 patients diagnosed with knee OA were randomly assigned to control group, intraarticularly administered hyaluronic acid alone, or to two treatment groups, hyaluronic acid together with 10 × 106 or 100 × 106 cultured autologous bone marrow-derived MSCs (BM-MSCs), and they were followed up for 12 months. After a follow up of 4 years adverse effects and clinical evolution, estimated using VAS and WOMAC scorings were reported.

There were no adverse effects after the BM-MSCs administration or during the follow-up. The BM-MSCs-administered patients showed considerable improvement according to VAS. At the end of follow up, the low-dose and high-dose groups changed from 5 (3, 7), 7 (5, 8) and 6 (4, 8) to 7 (6, 7), 2 (2, 5) and 3 (3, 4). Clinical improvement was observed in the patients receiving BM-MSCs according to the WOMAC scores. The control group exhibited an increase median value of 4 points (− 11;10) while Low-dose and High-dose groups showed values of − 18 (− 28;− 9) and − 10 (− 21;− 3) points, respectively (Low-dose vs. Control group p = 0.043). There were no clinical differences between the BM-MSCs receiving groups.

Source

Journal of Translational Medicine

Link to the source

https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1591-7

Original title of the article

Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: long-term follow up of a multicenter randomized controlled clinical trial (phase I/II)

Authors

Jose Maria Lamo-Espinosa et al.

SearchTags: 
Exploratory, Hyaluronic acid, Osteoarthritis, Knee, Nonsulfated glycosaminoglycan, Phase I/II multicenter randomized clinical trial, VAS, WOMAC scores
Log in or register to post comments